The entire line won’t close: four funds the marketplace seems to like will remain open. Meanwhile, Feldman says, they’ll revisit the old funds from time to time to see if they deserve another shot in the future.
The remaining funds will be:
- HealthShares Cancer (HHK)
- HealthShares European Drugs (HRJ)
- HealthShares Diagnostics (HHD)
- HealthShares Enabling Technologies (HHV)
HealthShares Enabling Technologies, however, is going to be renamed the Drug Discovery Tools Fund, and keep the same ticker symbol. A new fund will be joining the fold, as well: the HealthShares Asian Health, but it hasn’t begun trading.
Lower expense ratios for the remaining funds will be put in place, effective Oct. 1: for the cancer, diagnostic and drug discovery ETFs, the new expenses will be 0.60%, down from 0.75%. The European drugs will be 0.72%, down from 0.95%. The Asian health fund will be 0.95%. The four remaining funds will also get revamped benchmarks and number of constituents they’ll track, according to Murray Coleman for Index Universe.
The funds closing are:
- HealthShares Autoimmune-Inflammation (HHA)
- HealthShares Cardio Devices (HHE)
- HealthShares Cardiology (HRD)
- HealthShares Composite (HHQ)
- HealthShares Dermatology & Wound Care (HRW)
- HealthShares Emerging Cancer (HHJ)
- HealthShares European Medical Products & Devices (HHT)
- HealthShares GI/Gender Health (HHU)
- HealthShares Infectious Disease (HHG)
- HealthShares Metabolic-Endocrine Disorders (HHM)
- HealthShares Neuroscience (HHN)
- HealthShares Opthalmology (HHZ)
- HealthShares Orthopedic Repair (HHP)
- HealthShares Patient Care Services (HHB)
- HealthShares Respiratory/Pulmonary (HHR)